The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    February 2020

  • Pages
    318

  • View Count
    6612

Example Insights

Next Generation Immune Checkpoint Inhibitors and Stimulators - Context Next Generation Immune Checkpoint Inhibitors and Stimulators - Developers Next Generation Immune Checkpoint Inhibitors and Stimulators - Current Landscape
Next Generation Immune Checkpoint Inhibitors and Stimulators - Geographical Distribution Next Generation Immune Checkpoint Inhibitors and Stimulators - Key Targets Next Generation Immune Checkpoint Inhibitors and Stimulators - Capability Analysis
Next Generation Immune Checkpoint Inhibitors and Stimulators - Grant Analysis Next Generation Immune Checkpoint Inhibitors and Stimulators - Partnerships Next Generation Immune Checkpoint Inhibitors and Stimulators - Market Forecast
Next Generation Immune Checkpoint Inhibitors and Stimulators - Opportunity Analysis    

 

Overview

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients’ quality of life. There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb’s Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1 / PD-L1 inhibitor drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics. 

Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade / co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing / treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial growth in the foreseen future.

Scope of the Report

The “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both). 
  • A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
  • Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
  • An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals. 
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
  • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for next generation immune checkpoint inhibitors and stimulators, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus / lupus nephritis) [B] key immune checkpoint targets (B7-H3, CD38, CD40, CD47 and ICOS [C] mechanisms of action (inhibitory and costimulatory), [D] therapeutic modalities used (antibody fragment, monoclonal antibody and small molecule), [E] type of therapy (monotherapy, combination therapy and both), [F] route of administration (intravenous, subcutaneous and intracerebroventricular) and [G] key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for next generation immune checkpoint inhibitors and stimulators, in the short-midterm and long term.

Chapter 3 provides a general overview of cancer immunotherapy, highlighting important means of classification, focusing on next generation immune checkpoint modulators, including inhibitors and stimulators. The chapter lays emphasis on the role of immune checkpoints in cancer immunotherapy, including details on the various types of immune checkpoint targets, and their respective mechanisms of action. Further, it includes a discussion on the various challenges related to this class of therapeutics and highlights certain future perspectives.

Chapter 4 includes information on more than 300 molecules that are currently under development for the treatment of various cancer indications. It features a comprehensive analysis of pipeline molecules, highlighting, phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoint, mechanism of action (inhibitory or stimulatory, type of therapeutic modality (monoclonal antibody, antibody fragment, small molecule and others), route of administration, target therapeutic area(s), type of therapy (monotherapy, combination therapy and both). In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.

Chapter 5 includes detailed pipeline analysis of the therapies being developed for CD47. The chapter features an analysis of the pipeline molecules on the basis of phase of development, therapeutic modality, route of administration, target disease indication, type of therapy and information on their therapy developers and highlighting leading developers.

Chapter 6 includes detailed pipeline analysis of the therapies being developed for 4-1BB. It features an analysis of the pipeline molecules on the basis of phase of development, therapeutic modality, route of administration, target disease indication, type of therapy and information on their therapy developers and highlighting leading developers.

Chapter 7 provides a detailed analysis of more than 590 completed, ongoing and planned clinical studies of various next generation immune checkpoint therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of target immune checkpoint, target indication(s), key interventions, target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 8 provides detailed profiles of some of the leading stakeholders in this field (shortlisted based on number of pipeline products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent collaborations and an informed future outlook.

Chapter 9 provides an analysis of more than 490 grants that were awarded to research institutes engaged in next generation immune checkpoint inhibitors and stimulators related projects, in the period between 2016 and 2019 (till November) based on the important parameters associated with grants, such as the year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoint, and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, type of grant application and number of disease indications under investigation.

Chapter 10 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2017. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, and other agreements) that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular target immune checkpoint, and target disease indications.

Chapter 11 presents an insightful target competitiveness analysis, featuring a [A] three-dimensional bubble representation, highlighting the targets that are being evaluated for therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of  publications and number of grants and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters.

Chapter 12 features an analysis on 14 big pharma companies, highlighting the key focus areas of these players across various parameters, such as products’ stage of development, type of business model for the product under investigation, type of target immune checkpoint and target disease indications.

Chapter 13 features a detailed market forecast analysis, highlighting the likely growth of next generation immune checkpoint inhibitors and stimulators therapies till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target disease indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus / lupus nephritis), targets immune checkpoints (B7-H3, CD38, CD40, CD47 and ICOS), type of therapeutic modality (antibody fragment, monoclonal antibody and small molecule), routes of administration (intravenous, subcutaneous and intracerebroventricular) and key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the next generation inhibitors and stimulators industry.

Chapter 15 is a collection of interview transcripts of discussions held with key stakeholders in this market.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy

3.4. Immune Checkpoint Modulators
3.5. First Generation Immune Checkpoint Modulators
3.6. Next Generation Immune Checkpoint Modulators
3.6.1. Types of Next Generation Immune Checkpoint Modulators

3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy
3.8. Future Perspectives

4. CURRENT MARKET LANDSCAPE: MARKETED AND DEVELOPMENT PIPELINE
4.1. Chapter Overview
4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Immune Checkpoint
4.3.3. Analysis by Mechanism of Action
4.3.4. Analysis by Therapeutic Modality
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Popular Oncological Indication(s) and Popular Target Immune Checkpoint
4.3.9. Analysis by Popular Non-Oncological Indication(s) and Popular Target Immune Checkpoint
4.3.10. Analysis by Popular Disease Indication(s) and Popular Target Immune Checkpoint in Highest Phase of Development

4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
4.4.4. Popular Targets: Distribution by Number of Developers
4.4.5 World Map Representation: Analysis by Geography

5. MARKET LANDSCAPE: THERAPIES TARGETING CD47
5.1. Chapter Overview
5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies

5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Therapeutic Modality
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Target Disease Indication

5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size and Geographical Location
5.4.3. Leading Developers: Analysis by Number of Therapies
5.4.4. World Map Representation: Analysis by Geography

6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB
6.1. Chapter Overview
6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
6.3.1. Analysis by Phase of Development
6.3.2. Analysis by Therapeutic Modality
6.3.3. Analysis by Route of Administration
6.3.4. Analysis by Target Disease Indication

6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size and Geographical Location
6.4.3. Leading Developers: Analysis by Number of Therapies
6.4.4. World Map Representation: Analysis by Geography

7. CLINICAL TRIAL ANALYSIS 
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Players: Analysis by Number of Registered Trials
7.3.8. Word Cloud: Key Focus Areas
7.3.9. Analysis by Target Immune Checkpoint
7.3.10. Analysis by Target Therapeutic Area
7.3.11. Popular Indications: Analysis by Number of Registered Trials
7.3.12. Popular Interventions: Analysis by Number of Registered Trials
7.3.13. Geographical Analysis by Number of Registered Trials
7.3.14. Geographical Analysis by Number of Patients Enrolled

8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS
8.1. Chapter Overview

8.2. Bristol-Myers Squibb
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.2.4. Recent Developments and Future Outlook

8.3. GlaxoSmithKline
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.3.4. Recent Developments and Future Outlook

8.4. Incyte
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook

8.4. Novartis
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Trillium Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.5.4. Recent Developments and Future Outlook

9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Administering Institute Center
9.3.4. Analysis by Funding Institute Center
9.3.5. Analysis by Support Period
9.3.6. Analysis by Funding Institute Center and Support Period
9.3.7. Analysis by Type of Grant Application
9.3.8. Analysis by Purpose of Grant Award
9.3.9. Analysis by Grant Mechanism
9.3.10. Word Cloud: Emerging Focus Areas
9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
9.3.13. Analysis by Study Section Involved
9.3.14. Popular NIH Departments: Analysis by Number of Grants
9.3.15. Analysis by Types of Recipient Organizations
9.3.16. Popular Recipient Organizations: Analysis by Number of Grants 
9.3.17. Prominent Program Officers: Analysis by Number of Grants
9.3.18. Regional Analysis of Recipient Organizations

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models

10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Number of Partnership and Target Immune Checkpoint 
10.3.4. Analysis by Year of Partnership and Type of Partner
10.3.5. Analysis by Type of Partnership and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.4. Regional Analysis
10.4.1. Intercontinental and Intracontinental Agreements

11. TARGET COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Key Parameters
11.4. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
11.3.1. Four-Dimensional Bubble Analysis
11.3.2 Five-Dimensional Spider Web Analysis

12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Big Pharma Initiatives Focused on Next Generation Immune Checkpoint 
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Number of Targets
12.2.3. Analysis by Product Development Strategy
12.2.4. Analysis by Target Immune Checkpoint
12.2.5. Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint
12.2.6. Analysis by Type of Intervention
12.3. Analysis by Target Disease Indication(s)
12.3.1. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
12.3.2. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts

13.4.1. DARZALEX® (Janssen Pharmaceuticals)
13.4.1.1. Target Patient Population
13.4.1.2. Sales Forecast

13.4.2. SAR650984 (Sanofi)
13.4.2.1. Target Patient Population
13.4.2.2. Sales Forecast

13.4.3. RRx-001 (EpicentRx)
13.4.3.1. Target Patient Population
13.4.3.2. Sales Forecast

13.4.4. GSK3359609 (GlaxoSmithKline)
13.4.4.1. Target Patient Population
13.4.4.2. Sales Forecast

13.4.5. Omburtamab (Y-mAbs Therapeutics)
13.4.5.1. Target Patient Population
13.4.5.2. Sales Forecast

13.6.7. APXOO5M (Apogenix)
13.6.7.1. Target Patient Population
13.6.7.2. Sales Forecast

13.7.8. BI 655064 (Boehringer Ingelheim)
13.7.1. Target Patient Population
13.4.7.2. Sales Forecast

13.4.8. BMS-986015 (Bristol-Myers Squibb)
13.4.8.1. Target Patient Population
13.4.8.2. Sales Forecast

13.4.9. CFZ533 (Novartis)
13.4.9.1. Target Patient Population
13.4.9.2. Sales Forecast

13.4.10. GBR 830 (Glenmark)
13.4.10.1. Target Patient Population
13.4.10.2. Sales Forecast

13.4.11. KHK4083 (Kyowa Kirin)
13.4.11.1. Target Patient Population
13.4.11.2. Sales Forecast

13.12.13. LAG525 (Novartis)
13.12.13.1. Target Patient Population
13.12.13.2. Sales Forecast

13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region
13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in US, 2020-2030
13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, 2020-2030
13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, 2020-2030
13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, 2020-2030
13.5.5. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy 2020-2030
13.5.6. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, 2020-2030
13.5.7. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, 2022-2030
13.5.8. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, 2020-2030
13.5.9. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, 2020-2030

13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area
13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Indications, 2020-2030
13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-oncological Indications, 2024-2030

13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication
13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, 2024-2030
13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, 2025-2030
13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, 2024-2030
13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2025-2030
13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2025-2030
13.7.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2021-2030
13.7.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, 2024-2030
13.7.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2026-2030
13.7.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, 2020-2030
13.7.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2026-2030
13.7.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren’s Syndrome, 2024-2030
13.7.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative Colitis, 2024-2030

13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint
13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2026-2030
13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030
13.8.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030
13.8.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2021-2030
13.8.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2025-2030
13.8.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, 2024-2030
13.8.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, 2025-2030
13.8.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, 2024-2030

13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action
13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030
13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030

13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality
13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, 2020-2030
13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecules, 2020-2030

13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy
13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030
13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030
13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030

13.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration
13.12.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030
13.12.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030
13.12.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030

14. CONCLUDING REMARKS
14.1. Chapter Overview
14.2. Key Takeaways

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. IGM Biosciences
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Agnus Sinclair, Vice president Oncology and Bruce Keyt, Chief Scientific Officer, IGM Biosciences

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Global Age-Standardized Incidence Rates for Cancer, 2018 (per 100,000 Individuals)
Figure 3.1 Mechanism of Immunotherapies
Figure 3.3 Immune Checkpoint Targets
Figure 4.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
Figure 4.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
Figure 4.3 Next Generation Target Immune Checkpoint Inhibitors and Stimulators: Distribution by Highest Phase of Development
Figure 4.4 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
Figure 4.5 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
Figure 4.6 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
Figure 4.7 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Oncological Indications
Figure 4.8 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Non-Oncological Indications
Figure 4.9 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
Figure 4.10 Popular Oncological Indication(s): Distribution by Target Immune Checkpoints
Figure 4.11 Popular Non-Oncological Indication(s): Distribution by Target Immune Checkpoints
Figure 4.12 Popular Disease Indication(s): Distribution by Target Immune Checkpoint in Highest Phase of Development
Figure 4.13 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
Figure 4.14 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Geographical Location
Figure 4.15 Leading Developer Companies: Distribution by Number of Pipeline Therapies
Figure 4.16 Popular Targets: Distribution by Number of Developers
Figure 4.17 World Map Representation: Analysis by Geography
Figure 5.1 Immune Checkpoint Inhibitors for CD47: Distribution by Phase of Development
Figure 5.2 Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
Figure 5.3 Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
Figure 5.4 Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
Figure 5.5 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
Figure 5.6 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size and Geographical Location
Figure 5.7 Leading Developers: Distribution by Number of Pipeline Therapies for CD47
Figure 5.8 World Map Representation: Distribution by Geography
Figure 6.1 Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
Figure 6.2 Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
Figure 6.3 Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
Figure 6.4 Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
Figure 6.5 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
Figure 6.6 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Company Size and Geographical Location
Figure 6.7 Leading Developers: Distribution by Number of Therapies for 4-1BB
Figure 6.8 World Map Representation: Distribution by Geography
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.6 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, 1995-2019
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.9 Leading Players: Distribution by Number of Registered Trials
Figure 7.10 Word Cloud Analysis: Distribution by Focus Areas
Figure 7.11 Clinical Trial Analysis: Distribution by Target Immune Checkpoint
Figure 7.12 Clinical Trial Analysis: Distribution by Target Immune Checkpoint and Trial Registration Year
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Popular Indication(s): Analysis by Number of Registered Trials
Figure 7.15 Clinical Trial Analysis: Phase-Wise Distribution of Most Popular Indications
Figure 7.16 Popular Interventions: Analysis by Number of Number of Registered Trials
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 8.1 Bristol-Myers Squibb: Annual Revenues, 2015-2019 (USD Billion)
Figure 8.2 GlaxoSmithKline: Annual Revenues, 2015-2019 (USD Billion)
Figure 8.3 Incyte: Annual Revenues, 2015-2019 (USD Billion)
Figure 8.4 Novartis: Annual Revenues, 2015-2019 (USD Billion)
Figure 9.1 Grant Analysis: Distribution by Year of Grant Award, 2016-2019
Figure 9.2 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2019
Figure 9.3 Grant Analysis: Distribution by Administering Institute Center
Figure 9.4 Grant Analysis: Distribution by Funding Institute Center
Figure 9.5 Grant Analysis: Distribution by Support Period
Figure 9.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 9.7 Grant Analysis: Distribution by Type of Grant Application
Figure 9.8 Grant Analysis: Distribution by Purpose of Grant Award
Figure 9.9 Grant Analysis: Distribution by Grant Mechanism
Figure 9.10 Word Cloud: Emerging Focus Areas
Figure 9.11 Popular Target Immune Checkpoints: Distribution by Number of Grants
Figure 9.12 Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints (USD Million)
Figure 9.13 Grant Analysis: Distribution by Study Section Involved
Figure 9.14 Popular NIH Departments: Distribution by Number of Grants
Figure 9.15 Grant Analysis: Distribution by Types of Recipient Organizations
Figure 9.16 Prominent Program Officers: Distribution by Number of Grants
Figure 9.17 Popular Recipient Organizations: Distribution by Number of Grants
Figure 9.18 Grant Analysis: Distribution by Recipient Organizations
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2020
Figure 10.4. Partnerships and Collaborations: Distribution by Number of Partnerships and Target Immune Checkpoint
Figure 10.5. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.6. Partnerships and Collaborations: Distribution Type of Partnership and Type of Partner
Figure 10.7. Partnerships and Collaborations: Most Active Players
Figure 10.8. Partnerships and Collaborations: Regional Distribution
Figure 10.9. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1. Target Competitiveness Analysis: Four-Dimensional Bubble Analysis
Figure 11.2. Target Competitiveness Analysis: Five-Dimensional Spider Web Analysis
Figure 12.1. Big Pharma Players: Logo Landscape
Figure 12.2. Big Pharma Players: Analysis by Number of Initiatives
Figure 12.3. Big Pharma Players: Analysis by Number of Unique Targets
Figure 12.4. Big Pharma Players: Analysis by Product Development Strategy
Figure 12.5. Big Pharma Players: Heat Map Analysis by Target Immune Checkpoint
Figure 12.6. Big Pharma Players: Analysis by Product Development Strategy across Target Immune Checkpoint
Figure 12.7. Heat Map Representation: Distribution of Big Pharma Initiatives Across Target Immune Checkpoints and Highest Stage of Development
Figure 12.8. Grid Representation: Analysis by Product Development and Target Immune Checkpoint
Figure 12.9. Big Pharma Players: Analysis by Type of Intervention
Figure 12.10. Heat Map Representation: Big Pharma Initiatives Focused on Oncological Indications
Figure 12.11. Heat Map Representation: Big Pharma Initiatives Focused on Non-Oncological Indications
Figure 12.12. Heat Map Representation: Distribution of Big Pharma Initiatives Across Target Immune Checkpoints and Indication
Figure 13.1 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 (USD Million)
Figure 13.2 DARZALEX® Sales Forecast: 2020-2030 (USD Million)
Figure 13.3 SAR650984 Sales Forecast: 2020-2030 (USD Million)
Figure 13.4 RRx-001 Sales Forecast: 2021-2030 (USD Million)
Figure 13.5 GSK3359609 Sales Forecast: 2025-2030 (USD Million)
Figure 13.6 Enoblituzumab Sales Forecast: 2027-2030 (USD Million)
Figure 13.7 Omburtamab Sales Forecast:2026-2030 (USD Million)
Figure 13.8 APX005M Sales Forecast: 2024-2030 (USD Million)
Figure 13.9 BI 655064 Sales Forecast: 2024-2030 (USD Million)
Figure 13.10 BMS-986015 Sales Forecast: 2024-2030 (USD Million)
Figure 13.11 CFZ533 Sales Forecast: 2024-2030 (USD Million)
Figure 13.12 GBR 830 Sales Forecast: 2024: 2030 (USD Million)
Figure 13.13 KHK4083 Sales Forecast: 2024-2030 (USD Million)
Figure 13.14 LAG525 Sales Forecast: 2025-2030 (USD Million)
Figure 13.15 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region (USD Million)
Figure 13.16 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030 (USD Million)
Figure 13.17 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, 2020-2030 (USD Million)
Figure 13.18 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, 2020-2030 (USD Million)
Figure 13.19 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, 2020-2030 (USD Million)
Figure 13.20 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy, 2020-2030 (USD Million)
Figure 13.21 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, 2020-2030 (USD Million)
Figure 13.22 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, 2020-2030 (USD Million)
Figure 13.23 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, 2020-2030 (USD Million)
Figure 13.24 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, 2022-2030 (USD Million)
Figure 13.25 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area (USD Million)
Figure 13.26 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Indications, 2020-2030 (USD Million)
Figure 13.27 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030 (USD Million)
Figure 13.28 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, 2024-2030 (USD Million)
Figure 13.29 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, 2025-2030 (USD Million)
Figure 13.30 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, 2024-2030 (USD Million)
Figure 13.31 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2025-2030 (USD Million)
Figure 13.32 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2025-2030 (USD Million)
Figure 13.33 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2021-2030 (USD Million)
Figure 13.34 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, 2024-2030 (USD Million)
Figure 13.35 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2026-2030 (USD Million)
Figure 13.36 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, 2020-2030 (USD Million)
Figure 13.37 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2026-2030 (USD Million)
Figure 13.38 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren’s Syndrome, 2024-2030 (USD Million)
Figure 13.39 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative colitis, 2024-2030 (USD Million)
Figure 13.40 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint, 2027 and 2030
Figure 13.41 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2026-2030 (USD Million)
Figure 13.42 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030 (USD Million)
Figure 13.43 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2024-2030 (USD Million)
Figure 13.44 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2021-2030 (USD Million)
Figure 13.45 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2025-2030 (USD Million)
Figure 13.46 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, 2024-2030 (USD Million)
Figure 13.47 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, 2025-2030 (USD Million)
Figure 13.48 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, 2024-2030 (USD Million)
Figure 13.49 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action, 2025 and 2030
Figure 13.50 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030 (USD Million)
Figure 13.51 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2024-2030 (USD Million)
Figure 13.52 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality (USD Million)
Figure 13.53 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, 2020-2030 (USD Million)
Figure 13.54 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030 (USD Million)
Figure 13.55 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy, 2027 and 2030 (USD Million)
Figure 13.56 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030 (USD Million)
Figure 13.57 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030 (USD Million)
Figure 13.58 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2025-2030 (USD Million)
Figure 13.59 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration, 2027-2030 (USD Million)
Figure 13.60 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2026-2030 (USD Million)
Figure 13.61 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030 (USD Million)
Figure 13.62 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2024-2030 (USD Million)

List Of Tables

Table 3.1 Types of Immunotherapies and Associated Mechanisms of Action
Table 3.2 First Generation Immune Checkpoint Therapies
Table 4.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Target Immune Checkpoints
Table 4.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
Table 4.3 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
Table 5.1 Immune Checkpoint Inhibitors for CD47: Development Pipeline
Table 5.2 Immune Checkpoint Inhibitors for CD47: List of Therapy Developers
Table 6.1 Immune Checkpoint Stimulators for 4-1BB: Development Pipeline
Table 6.2 Immune Checkpoint Stimulators for 4-1BB: List of Therapy Developers
Table 8.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Companies Profiled
Table 8.2 Bristol- Myers Squibb: Company Snapshot
Table 8.3 Drug Profile: BMS-986213
Table 8.4 Drug Profile: BMS-986016
Table 8.5 Drug Profile: BMS-986258
Table 8.6 Drug Profile: BMS-986207
Table 8.7 Drug Profile: BMS-986179
Table 8.8 Drug Profile: BMS-663513
Table 8.9 Drug Profile: BMS-986178
Table 8.10 Drug Profile: BMS-936561
Table 8.11 Bristol-Myers Squibb: Future Outlook
Table 8.12 GlaxoSmithKline: Company Snapshot
Table 8.13 Drug Profile: GSK3359609
Table 8.14 Drug Profile: GSK2831781
Table 8.15 Drug Profile: GSK3174998
Table 8.16 Drug Profile: TSR-022
Table 8.17 Drug Profile: TSR-033
Table 8.18 Drug Profile: TSR-075
Table 8.19 GlaxoSmithKline: Future Outlook
Table 8.20 Incyte: Company Snapshot
Table 8.21 Drug Profile: INCB024360
Table 8.22 Drug Profile: INCB001158
Table 8.23 Drug Profile: INCAGN01876
Table 8.24 Drug Profile: INCAGN1876
Table 8.25 Drug Profile: INCAGN1949
Table 8.26 Drug Profile: MCLA-145
Table 8.27 Drug Profile: INCAGN2385
Table 8.28 Drug Profile: INCAGN2390
Table 8.29 Incyte: Future Outlook
Table 8.30 Novartis: Company Snapshot
Table 8.31 Drug Profile: CFZ533
Table 8.32 Drug Profile: MBG453
Table 8.33 Drug Profile: LAG525
Table 8.34 Drug Profile: GWN323
Table 8.35 Drug Profile: NZV930
Table 8.36 Novartis: Future Outlook
Table 8.37 Trillium Therapeutics: Company Snapshot
Table 8.38 Drug Profile: TTI-622-01
Table 8.39 Drug Profile: TTI-622-01
Table 8.40 Drug Profile: TTI-622
Table 8.41 Drug Profile: CD200 Monoclonal Antibodies
Table 8.42 Trillium Therapeutics: Future Outlook
Table 10.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
Table 13.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Forecasted Drug Candidates
Table 13.2 Darzalex: Target Patient Population (USD Million)
Table 13.3 SAR650984: Target Patient Population (USD Million)
Table 13.4 RRx-001: Target Patient Population (USD Million)
Table 13.5 GSK3359609: Target Patient Population (USD Million)
Table 13.6 Enoblituzumab: Target Patient Population (USD Million)
Table 13.7 Omburtamab: Target Patient Population (USD Million)
Table 13.8 APX005M: Target Patient Population (USD Million)
Table 13.9 BI 655064: Target Patient Population (USD Million)
Table 13.10 BMS-986015: Target Patient Population (USD Million)
Table 13.11 CFZ533: Target Patient Population (USD Million)
Table 13.12 GBR 830: Target Patient Population (USD Million)
Table 13.13 KHK4083: Target Patient Population (USD Million)
Table 13.13 LAG525: Target Patient Population (USD Million)
Table 14.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Summary of the Competitive Insights
Table 15.1 IGM Biosciences: Key Highlights
Table 16.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
Table 16.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
Table 16.3 Next Generation Target Immune Checkpoint Inhibitors and Stimulators: Distribution by Highest Phase of Development
Table 16.4 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
Table 16.5 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
Table 16.6 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
Table 16.7 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Oncological Indications
Table 16.8 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Non-Oncological Indications
Table 16.9 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
Table 16.10 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
Table 16.11 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Location of Headquarters
Table 16.12 Leading Developer Companies: Distribution by Number of Pipeline Therapies
Table 16.13 Leading Targets: Distribution by Number of Developers
Table 16.14 Word Map Representation: Distribution by Geography
Table 16.15 Immune Checkpoint Stimulators for CD47: Distribution by Phase of Development
Table 16.16 Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
Table 16.17 Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
Table 16.18 Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
Table 16.19 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
Table 16.20 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size
Table 16.21 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Location
Table 16.22 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Location
Table 16.23 Leading Developers: Distribution by Number of Pipeline Therapies for CD47
Table 16.24 Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
Table 16.25 Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
Table 16.26 Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
Table 16.27 Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
Table 16.28 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
Table 16.29 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Location
Table 16.30 Leading Developers: Distribution by Number of Pipeline Therapies for 4-1BB
Table 16.31 Clinical Trial Analysis: Distribution by Trial Status
Table 16.32 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Table 16.33 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patient’s Enrolled
Table 16.34 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 16.35 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 16.36 Clinical Trial Analysis: Distribution by Study Design
Table 16.37 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.38 Leading Players: Distribution by Number of Registered Trials
Table 16.39 Clinical Trial Analysis: Distribution by Target Immune Checkpoint
Table 16.40 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 16.41 Popular Indications: Distribution by Registered Trials
Table 16.42 Clinical Trial Analysis: Phase-Wise Distribution of Most Popular Indications
Table 16.43 Popular Interventions: Analysis by Number of Registered Trials
Table 16.44 Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 16.45 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 16.46 Bristol-Myers Squibb: Annual Revenues, 2015- 2019 (USD Billion)
Table 16.47 GlaxoSmithKline: Annual Revenues, 2015- 2019 (USD Billion)
Table 16.48 Incyte: Annual Revenues, 2015- 2019 (USD Billion)
Table 16.49 Novartis: Annual Revenues, 2015- 2019 (USD Billion)
Table 16.50 Grant Analysis: Distribution by Year of Grant Award, 2016-2019
Table 16.51 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2019
Table 16.52 Grant Analysis: Distribution by Administering Institute Center
Table 16.53 Grant Analysis: Distribution by Funding Institute Center
Table 16.54 Grant Analysis: Distribution by Support Period
Table 16.55 Grant Analysis: Distribution by Type of Grant Application
Table 16.56 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.57 Grant Analysis: Distribution by Grant Mechanism Popular Target Immune Checkpoints: Distribution by Number of Grants
Table 16.58 Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints
Table 16.59 Grant Analysis: Distribution by Study Section Involved
Table 16.60 Grant Analysis: Distribution by Types of Recipient Organizations
Table 16.61 Popular NIH Departments: Distribution by Number of Grants
Table 16.62 Prominent Program Officers: Distribution by Number of Grants
Table 16.63 Grant Analysis: Distribution by Recipient Organizations
Table 16.64 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Table 16.65 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.66 Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2020
Table 16.67 Partnerships and Collaborations: Distribution by Target Immune Checkpoint
Table 16.68 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 16.69 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 16.70 Most Active Players: Distribution by Number of Partnerships
Table 16.71 Partnership and Collaborations: Regional Distribution
Table 16.72 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 16.73 Big Pharma Players: Distribution by Number of Initiatives
Table 16.74 Big Pharma Plyers: Analysis by Number of Unique Targets
Table 16.75 Big Pharma Plyers: Analysis by Product Development Strategy
Table 16.76 Big Pharma Players: Analysis by Product Development Strategy across Target Immune Checkpoint
Table 16.77 Big Pharma Players: Analysis by Type of Intervention
Table 16.78 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.79 DARZALEX: Sales Forecast, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.80 SAR650984: Sales Forecast, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.81 RRx-001: Sales Forecast, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.82 GSK3359609: Sales Forecast, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.83 Enoblituzumab: Sales Forecast, 2027-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.84 Omburtamb: Sales Forecast, 2026-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.85 APXOO5M: Sales Forecast, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.86 BI 655064: Sales Forecast, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.87 BMS-986015: Sales Forecast, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.88 CFZ533: Sales Forecast, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.89 GBR 830: Sales Forecast, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.90 KHK4083: Sales Forecast, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.91 LAG525: Sales Forecast, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.92 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region (USD Million)
Table 16.93 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.94 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.95 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in EU4, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.96 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.97 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.98 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.99 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.100 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.101 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.102 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.103 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area (USD Million)
Table 16.104 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Disorders, 2020-2030 (USD Million)
Table 16.105 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-oncological Disorders, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.106 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.107 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.108 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.109 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.110 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.111 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.112 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.113 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.114 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.115 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2026-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.116 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren’s Syndrome, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.117 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative Colitis, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.118 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint, 2027 and 2030 (USD Million)
Table 16.119 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2026-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.120 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.121 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.122 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.123 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.124 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.125 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.126 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.127 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action (USD Million)
Table 16.128 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.129 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.130 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality, 2025 and 2030 (USD Million)
Table 16.131 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.132 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecules, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.133 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy, 2027 and 2030 (USD Million)
Table 16.134 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.135 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.136 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2025-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.137 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration, 2027 and 2020 (USD Million)
Table 16.138 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2026-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.139 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.140 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2024-2030: Conservative, Base and Optimistic Scenarios (USD Million)

Listed Companies

  1. AbbVie
  2. AbClon
  3. Abeome
  4. ABL Bio
  5. Abpro
  6. Acerta Pharma
  7. Acrus Biosciences
  8. Actinium Pharmaceuticals
  9. Adaptive Biotechnologies
  10. AdoRx Therapeutics
  11. Aduro Biotech
  12. Advaxis
  13. Agenus
  14. Agios Pharmaceuticals
  15. Alexion Pharmaceuticals
  16. Allergan
  17. Alligator Bioscience 
  18. Alpine Immune Sciences
  19. ALX Oncology
  20. Amgen
  21. Angel Therapeutics
  22. Anvil Biosciences (The company has been acquired)
  23. Apexigen
  24. Apogenix
  25. Aptevo Therapeutics
  26. Arch Oncology
  27. Arcus Biosciences
  28. ArQule
  29. Astellas Pharma
  30. Astex Pharmaceuticals
  31. AstraZeneca
  32. Atridia
  33. Aurigene Discovery Technologies
  34. Avacta Life Sciences
  35. Bach BioSciences
  36. BeiGene
  37. BinDeBio Group
  38. BIOCAD
  39. Biodextris
  40. BioNTech
  41. Bio-Techne
  42. Black Belt Therapeutics
  43. BliNK Biomedical
  44. bluebird bio
  45. Boehringer Ingelheim
  46. Boston Medical Center 
  47. Brigham and Women's Hospital
  48. Bristol-Myers Squibb
  49. Calithera Biosciences
  50. CALIXAR
  51. CASI Pharmaceuticals
  52. Catalent Biologics
  53. Celgene
  54. Celldex Therapeutics
  55. Center for Applied Medical Research 
  56. Centrose
  57. Checkpoint Therapeutics
  58. China National Biotec Group
  59. CleveXel Pharma
  60. Columbia University Irving Medical Center
  61. Compass Therapeutics
  62. Compugen
  63. Corvus Pharmaceuticals
  64. Crescendo Biologics
  65. CStone Pharmaceuticals
  66. Curis
  67. D5Pharma
  68. Daiichi Sankyo
  69. Distributed Bio
  70. DNAtrix
  71. Domain Therapeutics
  72. Dova Pharmaceuticals
  73. Dualogics
  74. Eisai
  75. Eli Lilly
  76. Elpiscience Biopharma
  77. ELSALYS BIOTECH
  78. EMulate Therapeutics
  79. EpicentRx
  80. FF Pharmaceuticals
  81. Five Prime Therapeutics
  82. Forty Seven
  83. Fred Hutchinson Cancer Research Center
  84. F-star
  85. Gateway Biologics
  86. Genentech
  87. Genmab
  88. Genomics Medicine Ireland
  89. Genosco
  90. GigaGen
  91. Gilead Sciences
  92. Glaxosmithkline
  93. Glenmark
  94. Glycotope 
  95. Hanmi Pharmaceutical
  96. HanX Biopharmaceuticals 
  97. Heat Biologics
  98. Hrain Biotechnology
  99. Hummingbird Bioscience
  100. IGM Biosciences
  101. I-Mab Biopharma
  102. Immatics
  103. ImmuneOncia Therapeutics
  104. ImmuneOnco Biopharmaceuticals
  105. ImmuNext
  106. Impetis Biosciences 
  107. Incyte
  108. Inhibrx
  109. Innate Pharma
  110. Innovent Biologics
  111. Institute for Research in Biomedicine
  112. InteRNA Technologies
  113. International Myeloma Foundation
  114. IO Biotech
  115. iOnctura
  116. iTeos Therapeutics
  117. Janssen Pharmaceuticals
  118. Jiangxi Qingfeng Pharmaceutical
  119. JN Biosciences
  120. Johns Hopkins University
  121. Johnson & Johnson
  122. Juventas Cell Therapy
  123. KAHR Medical
  124. Kiniksa Pharmaceuticals
  125. Kite Pharma
  126. Kleo Pharmaceuticals
  127. Kymab
  128. Kyowa Hakko Kirin
  129. Leap Therapeutics
  130. LG Chem
  131. LifeArc
  132. Lynkcell 
  133. Macrocure
  134. MacroGenics
  135. Marino Biotechnology
  136. Massachusetts General Hospital
  137. MedImmune
  138. Merck 
  139. Merus
  140. Moderna
  141. Molecular Partners
  142. Molecular Templates
  143. Momenta Pharmaceuticals
  144. Morphiex
  145. MorphoSys
  146. Mount Sinai Innovation Partners
  147. Nanjing Chia Tai Tianqing
  148. National Cancer Institute
  149. National Heart, Lung, and Blood Institute
  150. National Institute of Allergy and Infectious Diseases
  151. National Institute of Biomedical Imaging and Bioengineering
  152. National Institute of Dental and Craniofacial Research
  153. National Institute of Diabetes and Digestive and Kidney Diseases
  154. National Institute of Neurological Disorders
  155. NavarraBiomed-Biomedical Research Centre
  156. Navigen
  157. Neon Therapeutics
  158. NewLink Genetics
  159. NextCure
  160. Novartis
  161. Novimmune
  162. Numab Therapeutics
  163. Ogeda
  164. OncoArendi Therapeutics 
  165. Oncotelic
  166. Ono Pharmaceutical
  167. ORIC Pharmaceuticals
  168. OSE Immunotherapeutics
  169. Palobiofarma
  170. Pandion Therapeutics
  171. Paradigm Shift Therapeutics
  172. Parker Institute for Cancer Immunotherapy
  173. Pascal Biosciences
  174. Peloton Therapeutics
  175. PeptiDream
  176. PersonGen BioTherapeutics (Suzhou) 
  177. Pfizer
  178. PharmAbcine
  179. Pieris Pharmaceuticals
  180. Pinze Lifetechnology
  181. Potenza Therapeutics
  182. PsiOxus Therapeutics
  183. Roche
  184. Rubius Therapeutics
  185. Sanofi
  186. Sanquin
  187. Seattle Genetics
  188. Shanghai GeneChem
  189. Shattuck Labs
  190. Shire
  191. Sorrento Therapeutics
  192. Stanford University
  193. Surface Oncology
  194. Sutro Biopharma
  195. Swedish Orphan Biovitrum
  196. Symphogen
  197. Synthon International Holding
  198. Syros Pharmaceuticals
  199. Takeda Pharmaceutical
  200. Tarus Therapeutics 
  201. Tempest Therapeutics
  202. TESARO
  203. TG Therapeutics
  204. The University of Texas MD Anderson Cancer Center
  205. Tottori University
  206. TRACON Pharmaceuticals
  207. Trellis Biosciences
  208. TRIGR Therapeutics
  209. Trillium Therapeutics
  210. Tsinghua University
  211. Union Stem Cell & Gene Engineering
  212. University of California San Francisco
  213. University of California, Los Angeles
  214. University of California, San Diego
  215. University of Minnesota
  216. Vall d’Hebron Institute of Oncology
  217. Valo Therapeutics
  218. Viela Bio
  219. ViraTherapeutics 
  220. Vivoryon Therapeutics
  221. Washington University
  222. Waterstone Hanxbio 
  223. Xencor
  224. XOMA
  225. Y-Biologics
  226. Yale Cancer Center
  227. Yale University
  228. Y-mAbs Therapeutics
  229. Yuhan Pharmaceuticals
  230. Zai Lab
  231. Zymeworks

 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com